Stock ONC ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Oncolytics Biotech Inc.

Equities

ONC

CA6823108759

Delayed Toronto S.E.
Other stock markets
 14:30:04 01/05/2024 BST 		5-day change 1st Jan Change
1.52 CAD -0.65% Intraday chart for Oncolytics Biotech Inc. +3.40% -15.08%
04-11 Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA CI
04-11 Oncolytics Biotech Down 1.8% In US Premarket As Submits Type C Meeting Request to FDA MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Adjusts Price Target on Oncolytics Biotech to $5 From $15, Maintains Buy Rating
MT
Oncolytics Biotech Brief: Announcing Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep "Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate"
MT
Oncolytics Biotech Inc. Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial That Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate
CI
JonesTrading Initiates Oncolytics Biotech at Buy With $9 Price Target
MT
Canaccord Genuity Adjusts Price Target on Oncolytics Biotech to $5 From $6, Maintains Buy Rating
MT
Oncolytics Biotech Inc. Reports Interim Results from Phase 1/2 Goblet Study Showing A 70% Objective Response Rate in Pancreatic Cancer At the SITC Annual Meeting
CI
Oncolytics Biotech Brief: Reporting Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
MT
Maxim Initiates Oncolytics Biotech With Buy Rating, Sets Price Target at $3
MT
RBC Capital Keeps OutperformSpeculative on Oncolytics Biotech
MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk Rating, $6 TP on Oncolytics Biotech
MT
ONCOLYTICS BIOTECH : HC Wainwright Starts Oncolytics Biotech at Buy With $15 Price Target
MT
ONCOLYTICS BIOTECH : RBC Capital Keeps Outperform/Speculative Risk on Oncolytics Biotech After Q3
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. News Oncolytics Biotech Inc.
  5. Analyst Reco.